<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl5" position="float"><object-id pub-id-type="doi">10.7554/eLife.18082.011</object-id><label>Table 5.</label><caption><p>Antibiogram of <italic>K. pneumoniae</italic> causing bacteraemia in Northeast Thailand.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.18082.011">http://dx.doi.org/10.7554/eLife.18082.011</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Antibiotic category</th><th valign="top">Antibiotic agents</th><th valign="top">CAB <break/>(n&#160;=&#160;1010 patients)</th><th valign="top">HCAB <break/>(n&#160;=&#160;196 patients)</th><th valign="top">HAB <break/>(n&#160;=&#160;455 patients)</th><th valign="top">p values</th></tr></thead><tbody><tr><td rowspan="4" valign="top">Aminoglycosides</td><td valign="top">Gentamicin</td><td valign="top">94/999 (9%)</td><td valign="top">53/193 (27%)</td><td valign="top">265/444 (60%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Tobramycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Amikacin</td><td valign="top">17/815 (2%)</td><td valign="top">12/157 (8%)</td><td valign="top">109/398 (27%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Netilmicin</td><td valign="top">20/450 (4%)</td><td valign="top">23/112 (21%)</td><td valign="top">124/320 (39%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Anti-MRSA cephalosporins</td><td valign="top">Ceftaroline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Antipseudomonal penicillins + &#946; lactamase inhibitors</td><td valign="top">Ticarcillin-clauvanic acid</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Piperacillin-tazobactam</td><td valign="top">24/166 (14%)</td><td valign="top">14/32 (44%)</td><td valign="top">73/121 (60%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Carbapenems</td><td valign="top">Ertapenem</td><td valign="top">2/432 (0%)</td><td valign="top">1/100 (1%)</td><td valign="top">5/264 (2%)</td><td valign="top">0.17</td></tr><tr><td valign="top">Imipenem</td><td valign="top">1/778 (0%)</td><td valign="top">1/164 (1%)</td><td valign="top">2/408 (0%)</td><td valign="top">0.24</td></tr><tr><td valign="top">Meropenem</td><td valign="top">0/583 (0%)</td><td valign="top">1/113 (1%)</td><td valign="top">2/317 (1%)</td><td valign="top">0.10</td></tr><tr><td rowspan="2" valign="top">Non-extended spectrum cephalosporins</td><td valign="top">Cefazolin</td><td valign="top">76/319 (24%)</td><td valign="top">30/60 (50%)</td><td valign="top">101/127 (80%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefuroxime</td><td valign="top">81/478 (17%)</td><td valign="top">35/98 (36%)</td><td valign="top">161/231 (70%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="3" valign="top">Extended-spectrum cephalosporins</td><td valign="top">Cefotaxime</td><td valign="top">146/902 (16%)</td><td valign="top">71/173 (41%)</td><td valign="top">298/424 (70%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ceftazidime</td><td valign="top">124/927 (13%)</td><td valign="top">63/176 (36%)</td><td valign="top">295/430 (69%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Cefepime</td><td valign="top">5/100 (5%)</td><td valign="top">8/22 (36%)</td><td valign="top">25/51 (49%)</td><td valign="top">&lt;0.001</td></tr><tr><td rowspan="2" valign="top">Cephamycins</td><td valign="top">Cefoxitin</td><td valign="top">15/396 (4%)</td><td valign="top">10/95 (11%)</td><td valign="top">14/230 (6%)</td><td valign="top">0.03</td></tr><tr><td valign="top">Cefotetan</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Fluoroquinolones</td><td valign="top">Ciprofloxacin</td><td valign="top">143/894 (16%)</td><td valign="top">66/176 (38%)</td><td valign="top">187/430 (43%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Folate pathway inhibitors</td><td valign="top">Trimethoprim-sulphamethoxazole</td><td valign="top">198/876 (23%)</td><td valign="top">69/171 (40%)</td><td valign="top">219/407 (54%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Glycylcyclines</td><td valign="top">Tigecycline</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Monobactams</td><td valign="top">Aztreonam</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td rowspan="2" valign="top">Penicillins + &#946; lactamase inhibitors</td><td valign="top">Amoxicillin-clavulanic acid</td><td valign="top">131/945 (14%)</td><td valign="top">68/183 (37%)</td><td valign="top">291/443 (66%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Ampicillin-sulbactam</td><td valign="top">20/105 (19%)</td><td valign="top">9/17 (53%)</td><td valign="top">23/38 (61%)</td><td valign="top">&lt;0.001</td></tr><tr><td valign="top">Phenicols</td><td valign="top">Chloramphenicol</td><td valign="top">4/19 (21%)</td><td valign="top">0/2 (0%)</td><td valign="top">0/3 (0%)</td><td valign="top">&gt;0.99</td></tr><tr><td valign="top">Phosphonic acids</td><td valign="top">Fosfomycin</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">NA</td><td valign="top">-</td></tr><tr><td valign="top">Polymyxins</td><td valign="top">Colistin *</td><td valign="top">0/6 (0%)</td><td valign="top">0/2 (0%)</td><td valign="top">0/5 (0%)</td><td valign="top">-</td></tr><tr><td valign="top">MDR</td><td valign="top"/><td valign="top">146/1010 (14%)</td><td valign="top">71/196 (36%)</td><td valign="top">301/455 (66%)</td><td valign="top">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn id="tblfn9"><p>NOTE: Data are number of isolates demonstrating non-susceptible to the antimicrobial over the total number of isolates tested (%). CAB&#160;=&#160;Community-acquired bacteraemia, HCAB&#160;=&#160;Healthcare-associated bacteraemia, HAB&#160;= Hospital-acquired bacteraemia, and NA&#160;=&#160;Not available. The first isolate of each patient was used. MDR: non-susceptible to &#8805;1 agent in &#8805;3 antimicrobial categories.</p></fn><fn id="tblfn10"><p>* Defined by using an inhibition zone of &lt;11 mm.</p></fn></table-wrap-foot></table-wrap>